In fiscal year 2019, there will be approximately $1.9 billion in value-based incentive payments available to hospitals in the Hospital Value-Based Purchasing (VBP) Program, which is a budget-neutral program.
In fiscal year (FY) 2019, there will be approximately $1.9 billion in value-based incentive payments available to hospitals in the Hospital Value-Based Purchasing (VBP) Program, according to a new CMS fact sheet. The amount available is unchanged from FY 2018.
The Hospital VBP Program adjusts what hospitals receive in Medicare reimbursements under the Inpatient Prospective Payment System (IPPS), which bases payments on the quality of inpatient care provided to patients.
“This program is part of our long-standing effort to improve care across the entire healthcare delivery system, including hospital inpatient care, by tying Medicare payment to quality and cost measure performance,” CMS explained in the fact sheet.
According to CMS, more than 55% of hospitals will receive an increase in their Medicare payments. FY 2019 will represent the seventh year of the Hospital VBP Program, which affects payment for inpatient stays for approximately 2800 hospitals.
Hospitals’ incentive payments depend on their Total Performance Score (TPS), value-based incentive payment percentage, and the estimated amount available for value-based incentive payments. The TPS is based on performance scores in 4 domains:
The Hospital VBP Program is budget neutral, and in FY 2019, the highest-performing hospital will receive a net IPPS payment increase of 3.67% while the lowest-performing hospital will be hit with a 1.59% decrease. The average net payment adjustment will be 0.17%.
In the fact sheet, CMS noted that it views value-based purchasing as important for “revamping how care and services are paid for” as the United States moves to a system that pays for value.
“As we more closely link patient outcomes and costs to value-based hospital payment, the Hospital VBP Program not only aims for quality gains on paper, it also aims to promote a culture that prioritizes quality and value of care and better empowers patients and their healthcare providers through the public display of program results,” CMS concluded.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More